{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:07:52Z","timestamp":1788314872810,"version":"build-2803163510"},"reference-count":79,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/17425255.2023.2272593","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:40:52Z","timestamp":1697542852000},"page":"741-750","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity \u2013 a review of pharmacological and clinical data"],"prefix":"10.1080","volume":"19","author":[{"given":"Kajetan","family":"Kielbowski","sequence":"first","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Rosik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estera","family":"Bakinowska","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Gromowska","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Ustianowski","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Szostak","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0MD00051E"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.5.748.63584"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970048"},{"issue":"3","key":"e_1_3_4_8_1","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian H","year":"2007","unstructured":"Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168\u2013173.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei031"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2074987"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1667"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29518"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0301-7"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390214"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep101"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262040-00005"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259882"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101378"},{"issue":"5","key":"e_1_3_4_19_1","first-page":"958","article-title":"National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow up study","volume":"30","author":"Thomas E","year":"2003","unstructured":"Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow up study. J Rheumatol. 2003;30(5):958\u2013965.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06395-3"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2017.03.014"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00142-8"},{"issue":"5","key":"e_1_3_4_24_1","first-page":"264","article-title":"Lessons from the leucovorin shortages between 2009 and 2012 in a medicare advantage population: where do we go from here?","volume":"7","author":"Hayes MS","year":"2014","unstructured":"Hayes MS, Ward MA, Slabaugh SL, et al. Lessons from the leucovorin shortages between 2009 and 2012 in a medicare advantage population: where do we go from here? Am Health Drug Benefits. 2014;7(5):264\u2013270.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110467"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16351"},{"issue":"12","key":"e_1_3_4_27_1","first-page":"732","article-title":"Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity","volume":"38","author":"Rattu MA","year":"2013","unstructured":"Rattu MA, Shah N, Lee JM, et al. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T. 2013;38(12):732\u2013744.","journal-title":"P T"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(84)90192-6"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1985.tb08860.x"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(97)00191-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2016.06.015"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201800186"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10930-009-9211-2"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3252-8_23"},{"key":"e_1_3_4_35_1","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/voraxaze-epar-product-information_en.pdf"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007311571"},{"issue":"3","key":"e_1_3_4_37_1","first-page":"894","article-title":"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid","volume":"294","author":"Widemann BC","year":"2000","unstructured":"Widemann BC, Sung E, Anderson L, et al. Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther. 2000;294(3):894\u2013901.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1010"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2125"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01144-3"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0582-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2009.04.005"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0243"},{"key":"e_1_3_4_44_1","unstructured":"VORAXAZE (glucarpidase). Package insert. BTG International Inc; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2019\/125327s064lbl.pdf"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4540"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1360"},{"issue":"1","key":"e_1_3_4_47_1","first-page":"36","article-title":"Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature","volume":"76","author":"Boelens AD","year":"2018","unstructured":"Boelens AD, Math\u00f4t RAA, Vlaar APJ, et al. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. Neth J Med. 2018;76(1):36\u201339.","journal-title":"Neth J Med"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946464"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/2054358119895078"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-11-1299"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602337"},{"key":"e_1_3_4_52_1","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (version 2.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"e_1_3_4_53_1","unstructured":"National Comprehensive Cancer Network. B cell lymphomas (version 5.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"e_1_3_4_54_1","unstructured":"National Comprehensive Cancer Network. Pediatric acute lymphoblastic leukemia (version 1.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ped_all.pdf"},{"key":"e_1_3_4_55_1","unstructured":"National Comprehensive Cancer Network. Pediatric aggressive mature B-Cell lymphomas (version 1.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ped_b-cell.pdf"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30506"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.006"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfu093"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2145"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1846733"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221079568"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X17705050"},{"issue":"5","key":"e_1_3_4_63_1","first-page":"322","article-title":"Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure","volume":"11","author":"Trifilio S","year":"2013","unstructured":"Trifilio S, Ma S, Petrich A. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure. Clin Adv Hematol Oncol. 2013;11(5):322\u2013323.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04361-8"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25395"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09164-x"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08030621"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1159\/000185335"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S188786"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000515"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27378"},{"key":"e_1_3_4_72_1","unstructured":"Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS. https:\/\/ClinicalTrials.gov\/show\/NCT05022797"},{"key":"e_1_3_4_73_1","unstructured":"Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma. https:\/\/ClinicalTrials.gov\/show\/NCT03960177"},{"key":"e_1_3_4_74_1","unstructured":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma. https:\/\/ClinicalTrials.gov\/show\/NCT03684980"},{"key":"e_1_3_4_75_1","unstructured":"Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma. https:\/\/ClinicalTrials.gov\/show\/NCT05135858"},{"key":"e_1_3_4_76_1","unstructured":"A Phase I\/II Study to Investigate the Use of VORAXAZE\u2122 as Intended Intervention in Patients With CNSL. https:\/\/ClinicalTrials.gov\/show\/NCT04841434"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e20648"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.09.006"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0910-2"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20255"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190012442717"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2023.2272593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T01:48:19Z","timestamp":1727228899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2023.2272593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/17425255.2023.2272593"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2023.2272593","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}